Recent advances in histamine H3/H4 receptor ligands

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 851-865

  Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

A 304121; AEIC; Agonist; Allergy; Antagonists; BP 2 94; Cardiac dysfunction; Ciproxifan; Clobenpropit; Colitis; Drug abuse; Dyskinesia; Epilepsy; FUB 407; FUB 649; GT 2331; H3; H4; Hitamine; Immune modulation; Inflammation; Inverse agonists; JB 98064; Learning; Memory; Non imidazole compound; Obesity; Partial agonists; Proxyfan; Schizophrenia; Sleep disorders; Thioperamide; UCL 1470

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA METHYLHISTAMINE; BP 2 94; CIPRALISANT; CIPROXIFAN; CLOBENPROPIT; FUB 407; GT 2331; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; HISTAMINE RECEPTOR; IMETIT; IMIDAZOLE DERIVATIVE; IMOPROXIFAN; LEVODOPA; MORPHINE; N METHYLHISTAMINE; NEUROLEPTIC AGENT; NITRILE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PRODRUG; PROTON PUMP INHIBITOR; THIOPERAMIDE; UCL 1470; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; CLINICAL STUDY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOLECULAR HYBRIDIZATION; MOUSE; NONHUMAN; OBESITY; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION;

EID: 0038647720     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.851     Document Type: Review

References (129)

1. 3) of histamine receptors. Nature (1983) 302:832-837.
2. 3 heteroreceptors. Fundam. Clin. Pharmacol. (1994) 8(2):128-137.
3. WATANABE T, TIMMERMAN H, YANAI K (Eds). Histamine research in the new millenium. Elsevier Science Publishers, Amsterdam, The Netherlands (2001).
4. 3 receptor agonist and antagonist on histamine co-transmitter expression in rat brain. J. Neural. Transm. (2002) 109(3):293-306.
5. LEURS R, SMIT MJ, TIMMERMAN H: Molecular pharmacological aspects of histamine receptors. Pharmacol. Ther. (1995) 66(3):413-463.
6. 3 receptor. Mol. Pharmacol. (1999) 55(6):1101-1107.
7. 3 receptor. Eur. Neuropsychopharmacol. (2001) 11(6):441-448.
8. BAKKER RA, TIMMERMAN H, LEURS R: Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin. Allergy Immunol. (2002) 17:27-64.
9. 3 histamine receptor isoforms: new therapeutic targets in the CNS? Curr. Opin. Investig. Drugs (2001) 2(10):1428-1431.
10. 3 receptor. Neuropharmacology (2002) 42(7):929-940.
11. 3 receptor and its gene transcripts in rat brain. Neuroscience (2002) 114(1):173-193.
12. 3 autoreceptors modulate histamine synthesis through cAMP pathway. Mol. Pharmacol. (2002) 61(1):239-245.
13. 3 receptor isoforms with different brain expression and signaling properties. Mol. Pharmacol. (2001) 59(1):1-8.
14. 3 receptor regulates histamine neurones in brain. Nature (2000) 408:860-864.
15. 3 antagonists. J. Pharmacol. Exp. Ther. (2001) 299(3):908-914.
16. 3 receptors. Br. J. Pharmacol. (2002) 135(2):383-392.
17. ODA T, MORIKAWA N, SAITOY, MASUHO Y, MATSUMOTO S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786.
18. HOUGH LB: Genomics meets histamine receptors: new subtypes, new receptors. J. Pharmacol. Exp. Ther. (2001) 59(3):415-419.
19. STARK H, SCHLEGEL B, SIPPL W: News on old histamine I. A new member in the receptor family. Pharm. Unsere Zeit (2003) 32:92-93.
20. 4-receptor gene. Biochem. Biophys. Res. Comm. (2001) 284:301-309.
21. 3 receptors: stimulation of IL-10 production. J. Immunol. (2000) 164(6):2964-2970.
22. SCHNEIDER E, ROLLI-DERKINDEREN M, AROCK M, DY M: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. (2002) 23(5):255-263.
23. 3 receptor antagonists. Expert Opin. Ther. Patents (2000) 10(7):1045-1055.
24. 3 receptor and its ligands. Prog. Med. Chem. (2001) 38:279-308.
25. BROWN RE, STEVENS DR, HAAS HL: The physiology of brain histamine. Prog. Neurobiol. (2001) 63(6):637-672.
26. 3 receptor agonists and antagonists. Trends Pharmacol. Sci. (1998) 19(5):177-183.
27. HAAS H, PANULA P: The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. (2003) 4:121-130.
28. 3-receptors. In: Biochemistry and Methology (Volume 16). The Histamine Receptor. Schwartz JC, Haas HL (Eds), Wiley-Liss, New York (1992):57-72.
29. 3-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency. J. Med. Chem. (2000) 43(17):3335-3343.
30. 3-receptors. Nature (1987) 327(6118):117-123.
31. 3-receptor. Eur. J. Med. Chem. (1992) 27:511-517.
32. 3-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds. J. Med. Chem. (2000) 43(21):3987-3994.
33. 3-receptor antagonist. J. Pharmacol. Exp. Ther. (1998) 287(2 ):658-666.
34. 3-receptor antagonist. Arch. Pharm. (Weinheim) (2000) 333(9):315-316.
35. 3 receptor agonist, 4-(1H-imidazol-4-ylmethyl)piperidine. J. Med. Chem. (1994) 37(3 ):332-333.
36. MARTINEZ AC, PRIETO D, HERNANDEZ M, GARCIA-SACRISTAN A, BENEDITO S: Contractile response of horse deep dorsal penile vein to histamine. Int. J. Impot. Res. (2002) 14(2):85-92.
37. 3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc. Natl. Acad. Sci. USA (2002) 99(1):501-506.
38. + exchange: a novel protective mechanism in myocardial ischemia. Proc. Natl. Acad. Sci. USA (2001) 98(5):2855-2859.
39. 3-receptors: a new frontier in myocardial ischemia. J. Pharmacol. Exp. Ther. (2000) 292:825-830.
40. 3-receptor agonists in myocardial infarction. Expert Opin. Investig. Drugs (2000) 9(11):2537-2542.
41. 3-receptor differ in their gastroprotective activity in the rat. Inflamm. Res. (2002) 51(Suppl.1):S75-S76.
42. 3-receptor antagonists inhibit gastroprotection by (R)-α-methylhistamine in the rat. Br. J. Pharmacol. (2000) 129(8):1597-1600.
43. PANULA P, LINTUNEN M, KARLSTEDT K: Histamine in brain development and tumors. Semin. Cancer Biol. (2000) 10(1):11-14.
44. 3 receptors modulate cell proliferation and migration in rat oxyntic mucosa. Br. J. Pharmacol. (2002) 137(2):237-244.
45. 3 receptors in the control of gastrointestinal motility: An overview. J. Physiol. Paris (2001) 95(1-6):67-74.
46. SCHWARTZ JC, ARRANG JM: Histamine. In: Neuropsychopharmacology: the fifth generation of progress. Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), Lipincott, Williams & Wilkins, Philadelphia, USA (2002):179-190.
47. 3-receptor agonist prodrug. J. Pharmacol. Exp. Ther. (2000) 295(1):219-225.
48. 3-receptor activation induces mechanical but not thermal antinociception. Program No. 54.1 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC, USA (2002):CD-ROM.
49. 3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology(1996) 15(1):31-35.
50. JACOBS EH, YAMATODANI A, TIMMERMAN H: Is histamine the final neurotransmitter in entrainment of circadian rhythms in mammals? Trends Pharmacol. Sci. (2000) 21:293-298.
51. MATSUBARA T, MOSKOWITZ MA, HUANG Z: UK-14,304, R(-)-α-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. Eur. J. Pharmacol. (1992) 224(2-3):145-150.
52. GUERRERO RO, CARDENAS MA, OCAMPO AA, PACHECO MF: Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache (1999) 39(8):576-580.
53. BEZARD E, BROTCHIE JM, GROSS CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. (2001) 2(8):577-588.
54. 3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat. Disord. (2000) 6(3):159-164.
55. ITO C: The role of brain histamine in acute and chronic stresses. Biomed. Pharmacother. (2000) 54(5):263-267.
56. NATH C, GUPTA MB. Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol. Biochem. Behav. (2001) 68(4):777-782.
57. 3-receptor agonist, on the Morris water-maze in rat. Behav. Brain Res. (2002) 129(1-2):77-82.
58. FOZARD JR: BP-294 Ste Civile Bioprojet. Curr. Opin. Investig. Drugs (2000) 1(1):86-89.
59. 3-receptor agonist. Curr. Med. Chem. (2001) 8:1329-1340.
60. 3-receptor agonist (R)-α-methylhistamine. Bioorg. Med. Chem. (2001) 9:191-198.
61. 3 receptor with high in vitro and in vivo activity. J. Med. Chem. (1999) 42:4269-4274.
62. 3 receptor agonist/antagonist properties. J. Med. Chem. (2002) 45:4000-4010.
63. 3 receptor lacking a nitrogen atom in the side chain. 29th Meeting of the European Histamine Research Society Nemi (Rome), Italy (2000) Abstract 31.
64. KENAKIN TP: Pharmacological proteus? Trends Pharmacol. Sci. (1995) 16:256-258.
65. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. (2002) 131(1-2):151-161.
66. 3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. (2000) 12(11):3823-3832.
67. PASSANI MB, BLANDINA P: The neuronal histaminergic system in cognition. Curr. Med. Chem. Cen. Nerv. Syst. Agents [In press].
68. HALPERN MT: GT-2331 (Gliatech., Inc.). Curr. Opin. Centr. Peripher. Nerv. Syst. Invest. Drugs (1999) 1:524-527.
69. FLETCHER L: Guilford halts Gliatech deal. Nat. Biotech. (2000) 18(10):1023.
70. 3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci. (2002) 22(16):7272-7280.
71. 3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur. J. Neurosci. (2003) 17(2):307-314.
72. 3 receptor mechanisms. FASEB J. (2001)15(6 ):1074-1076.
73. MORI T, NARITA M, ONODERA K, SUZUKI T: Modulation of the discriminative stimulus effects of cocaine and methamphetamine by the histaminergic system. Nihon Shinkei Seishin Yakurigaku Zasshi (2002) 22(3):73-78.
74. 3-receptors following destruction of the ascending dopaminergic neurones. Br. J. Pharmacol. (1996) 118(3):585-592.
75. KUBOTA Y, ITO C, SAKURAI E, SAKURAI E, WATANABE T, OHTSU H: Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J. Neurochem. (2002) 83(4):837-845.
76. 3 receptors. Mol. Pharmacol. (2002) 62(2):389-97; Erratum: Mol. Pharmacol. (2002) 62(3 ):763.
77. 3 receptors results in change in brain histamine tone leading to an obese phenotype. J. Clin. Invest. (2002) 110:1791-1799.
78. 3 receptor ligands in a new mouse dipsogenia model. Pharmacol. Biochem. Behav. (2002) 72(3):741-750.
79. 3 receptor antagonists A-304121 and A-317920: II. in vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. (2003) [In press].
80. 3-receptor ligands: a possible role in the mechanism and management of epilepsy. Pharmacol. Biochem. Behav. (2001) 68(4):735-741.
81. 1-agonist betahistine on amygdaloid kindled seizures. Epilepsy Res. (2000) 40(2-3):141-145.
82. 3 receptor blockade on venous return and splanchnic hemodynamics in experimental bacteremia. Crit. Care Med. (2002) 30(3):628-636.
83. 3 receptor antagonists. Bioorg. Med. Chem. (2002) 10(2):425-432.
84. 3-receptor antagonists. Eur. J. Pharm. Sci. (2002) 15(4):367-378.
85. 3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template. Bioorg. Med. Chem. Lett. (2002) 12:937-941.
86. 3-antagonists endowed with NO-donor properties. Bioorg. Med. Chem. (2003) 11:1197-1205.
87. 3 receptor affinities. Bioorg. Med. Chem. (2003) 11:2163-2174.
88. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology (2002) 66(3):128-135.
89. ARRANG JM, GARBARG M, QUACH TT, DAM TRUNG TUONG M, YERAMIAN E, SCHWARTZ JC: Actions of betahistine at histamine receptors in the brain. Eur. J. Pharmacol. (1985) 111(1):73-84.
90. TIGHILET B, TROTTIER S, MOURRE C, CHOTARD C, LACOUR M: Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms. Eur. J. Pharmacol. (2002) 446(1-3):63-73.
91. 3 receptors. Psychopharmacology (Berl.) (1994) 116(4):464-468.
92. 3 histamine receptors in the rat cochlea. NeuroReport (2003) 14(3):423-425.
93. 3-receptor antagonists. Arch. Pharm. (Weinheim) (1998) 331(12):395-404.
94. 1 blocking activities. Farmaco (1999) 54(10):684-694.
95. 3 antagonists. Arch. Pharm. (Weinheim) (1999) 332(11):389-398.
96. 3 receptor antagonists. J. Med. Chem. (2000) 43(12 ):2362-2370.
97. 3-receptor antagonists of the carbamate series: variation of the spacer length. Pharmazie (2001) 56(12):927-932.
98. 3-receptor antagonists. Bioorg. Med. Chem. (2002) 10(8):2535-2542.
99. 3 receptor antagonists of the carbamate series: the influence of the additional ether functionality. Pharmazie (2002) 57(12):791-795.
100. 3-receptor antagonists. Eur. J. Pharm. Sci. (2001) 13(3 ):249-259.
101. 3-receptor antagonists. Naunyn Schmiedeberg's Arch. Pharmacol. (2003) 367(1):43-50.
102. 3 receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:3309-3312.
103. FAGHIH R, DWIGHT W, VASUDEVAN A et al.: Aminoalkylbiphenylnitrils as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett. (2002) 12:3077-3079.
104. 3 receptor ligands. Part 1. Bioorg. Med. Chem. Lett. (2002) 12(15):2031-2034.
105. 3 receptor ligands. Part 2: binding preference for D-amino acids motifs. Bioorg. Med. Chem. Lett. (2002) 12(15):2035-2037.
106. 3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. (2003) [In press].
107. 3 receptors: role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. (2000) 131(7):1247-1250.
108. 3 receptors. Bioorg. Med. Chem. Lett. (2001) 11(7):951-954.
109. 3 receptor. J. Pharmacol. Exp. Ther. (2002) 301(2):451-458.
110. 3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(18):2643-2646.
111. 3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl) piperidines and related compounds. J. Med. Chem. (2003) 46:1523-1530.
112. 3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release. Eur. J. Neurosci. (2002) 16(3):521-528.
113. 3 receptor ligands with combined inhibitory histamine N-methyltransferase activity. J. Med. Chem. (2002) 45(5):1128-1141.
114. 3 receptor revealed. Br. J. Pharmacol. (1995) 116(4):2315-2321.
115. 3 receptor-mediated ion current in NG 108-15 cells. Eur. J. Pharmacol. (1998) 361(2-3):261-268.
116. VOROBJEV VS, SHARONOVA IN, WALSH IB, HAAS HL: Histamine potentiates N-methyl-D-aspartate responses in acutely isolated hippocampal neurons. Neuron (1993) 11:837-844.
117. BEKKERS JM: Enhancement of histamine of NMDA-mediated synaptic transmission in the hippocampus. Science (1993) 261:104-106.
118. 4 receptor. Mol. Pharmacol. (2002) 62:38-47.
119. 4) expressed in bone marrow. Mol. Pharmacol. (2001) 59(3):420-426.
120. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. (2003) [In press].
121. 4 receptor on human eosinophils-role in eosinophil chemotaxis. J. Recept. Signal. Transduct. Res. (2002) 22(1-4):431-448.
122. + T cells. J. Pharmacol. Exp. Ther. (2002) 303(1):300-307.
123. 4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. (2001) 299(1):121-130.
124. 2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling. J. Neurosci. (2001) 21(9):2974-2982.
125. 3 receptor, having a cis-cyclopropane structure. J. Med. Chem. (2003) 46:1980-1988.
126. 3 receptors. Mol. Pharmacol. (2003) 63(2):378-382.
127. 3 receptor antagonist. Bioorg. Med. Chem. Lett. (2003) 13(7 ):1325-1328.
128. MILLÁN-GUERRERO RO, PINEDA-LUCATERO AG, HERNÁNDEZ-BENJAMÍN T, TENE CE, PACHECO MF: Na-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. Headache (2003) 43:389-394.
129. 3 receptor antagonist. 32nd Annual Meeting of the European Histamine Research Society. Noordwijkerhout, The Netherlands (2003) Abstract 88.